MILAN, July 30 (Reuters) - The head of Italian group

Recordati expects treatments for rare diseases to be

exempted from the 15% tariff the United States plans to impose

on imported European pharmaceutical products, he said on

Wednesday.

"From what we know, rare diseases get a special, better

treatment and are excluded from any tariffs," Chief Executive

Robert Koremans said during a conference call on the

pharmaceutical company's first-half results.

"It seems to be manageable," he added, referring to the

potential impact of the U.S. measures on the company's results.

Treatments for rare diseases are an important part of

Recordati's business, contributing revenues of 515.7 million

euros in the first half of 2025.

Under a framework trade deal announced between U.S.

President Donald Trump and the European Union on Sunday, the

White House says EU pharmaceuticals will be subject to 15%

tariffs.